Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine

Pancreatic ductal adenocarcinoma (PDAC) is among the most deadly solid tumours. This is due to a generally late-stage diagnosis of a primarily treatment-refractory disease. Several large-scale sequencing and mass spectrometry approaches have identified key drivers of this disease and in doing so hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Conway, James RW, Herrmann, David, Evans, TR Jeffry, Morton, Jennifer P, Timpson, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Recent Advances in Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580874/
https://www.ncbi.nlm.nih.gov/pubmed/30396902
http://dx.doi.org/10.1136/gutjnl-2018-316822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580874/
https://www.ncbi.nlm.nih.gov/pubmed/30396902
http://dx.doi.org/10.1136/gutjnl-2018-316822

Ejemplares similares